When a basal cell-specific marker (34βE12 or p63) is negative in an atypical focus, can the diagnosis of adenocarcinoma be rendered? By the same token, if 34βE12- or p63-positive cells are present, can carcinoma be ruled out?
The loss of the basal cell layer is a hallmark of adenocarcinoma of the prostate. Generally speaking, the absence of basal cells as demonstrated by immunohistochemical technique provides strong support for the diagnosis of adenocarcinoma. If an atypical lesion contains basal cells (seen by immunostaining), the diagnosis of adenocarcinoma should be avoided.
KeywordsProstate Cancer Basal Cell Prostate Adenocarcinoma Prostatic Intraepithelial Neoplasia Basal Cell Layer
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Yang XI, Lecksell K, Gaudin P, Epstein JI (1999) Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 23:147–152.PubMedCrossRefGoogle Scholar
Oliai BR, Kahane H, Epstein JI (2002) Can basal cells be seen in adenocarcinoma of the prostate? Am J Surg Pathol 26;1151–1160.PubMedCrossRefGoogle Scholar
Varma M, Linden MD, Amin MB (1999) Effect of formalin fixation and epitope retrieval techniques on antibody 34βE12 immunostaining of prostatic tissue. Mod Pathol 12:472–478.PubMedGoogle Scholar